Core Viewpoint - McCormick's Q1 results initially appeared strong but later perceptions changed due to additional news, leading to a maintained hold rating for the stock [1] Financial Performance - Sales reached approximately $1.87 billion, reflecting a nearly 17% year-over-year increase, surpassing estimates by $80 million; however, most growth was driven by acquisitions, with organic growth at only 1.2% [2] - Total consumer sales grew by 24.5%, primarily due to acquisitions, while organic growth was 1.8%; a significant acquisition was McCormick de Mexico, where the company increased its stake to over 75% [2] - Non-GAAP earnings for Q1 were $0.66, exceeding estimates by 7 cents; gross profit margin improved by 20 basis points to 37.8%, and adjusted gross profit margin increased by 100 basis points to 38.6% [3] - GAAP operating income decreased by 190 basis points to 12.1%, while non-GAAP operating income rose by 30 basis points to 14.3%; the bottom line surged by 528% to $3.77 due to a non-cash gain from the remeasurement of the McCormick de Mexico stake [3] Financial Position - At the end of Q1, McCormick had approximately $178 million in cash and equivalents, against long-term debt of $3.6 billion [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 MINISO Group Holding Limited 名創優品集團控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：9896） 內幕消息 截至2025年12月31日止財政年度 初步財務表現及 董事會會議日期 本公告乃由名創優品集團控股有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.09(2)(a)條 及《證券及期貨條例》（香港法例第571章）第XIVA部項下的內幕消息條文（定義見 上市規則）而刊發。 本公司董事（「董事」）會（「董事會」）謹此宣佈，根據對未經審計綜合管理賬目之初 步審閱及評估，本集團預期截至2025年12月31日止財政年度（「2025財政年度」） 將錄得收入約人民幣21,440百萬元至人民幣21,445百萬元，同比增長約26%。本 公司預計2025財政年度將錄得經營利潤約人民幣3,300百萬元至人民 ...

Financial Performance - The company's Q4 revenue reached $4.499 billion, representing a year-over-year increase of 10.54%, with net profit attributable to shareholders at $353 million, a significant growth of 345.14% [1] - For the full year 2025, total revenue was $16.603 billion, up 8.16%, and net profit attributable to shareholders was $2.079 billion, reflecting a growth of 44.27% [2] - The gross margin for the year remained stable at 52.41%, while the operating profit margin was 21.97% [2] Cash Flow and Capital Management - The company reported free cash flow of $1.505 billion for the year, with capital expenditures controlled at 3.03% of revenue [2] - As of September 30, 2025, the remaining amount for the stock repurchase plan was approximately $249 million, and the dividend per share was $0.92, with a payout ratio of 60.13% [3] Operational Insights - Management highlighted that product mix optimization and supply chain management helped mitigate some of the cost pressures from raw materials, such as coffee beans [4] - An analysis from Bank of America indicated that the company needs to implement pricing strategies to address rising costs, while being mindful of consumer price sensitivity [4]

FY 2025 PRELIMINARY RESULTS unaudited data TODAY'S PRESENTERS CHIEF FINANCIAL OFFICER MARGHERITA SACERDOTI HEAD OF INVESTOR RELATIONS & SUSTAINABILITY MARCO ZAMMARCHI ALBERTO GALASSI CHIEF EXECUTIVE OFFICER TBD 2 TODAY'S AGENDA | 1 | Key Highlights | | --- | --- | | 2 | Business Dynamics | | 3 | Financial Results | | 4 | Final Remarks | | Q&A | | 3 Key Highlights 01 01 Key Highlights TURNING STRATEGY INTO RESULTS: OUTPERFORMED CONSENSUS & REFERENCE MARKET, WITH FY'25 GUIDANCE FULLY ACHIEVED ORDER BACKLOG4 R ...

Core Viewpoint - Bruker Corporation is facing challenges in maintaining profit margins despite exceeding revenue estimates, leading to a cautious outlook from analysts [5][6]. Financial Performance - Bruker reported Q4 2025 revenue of $977.2 million, a slight decline of 0.2% year-over-year, but above the Zacks Consensus Estimate of $966.4 million, resulting in a positive surprise of 1.12% [2][6]. - The company's EPS for Q4 2025 was $0.59, which fell short of the consensus estimate of $0.65, representing a negative surprise of 9.23% and a decline from the previous year's EPS of $0.76 [3][6]. Stock Performance - The current stock price of $37.51 reflects an approximate decrease of 11.60% from previous levels, with a market capitalization of about $5.7 billion [4]. - Over the past year, BRKR's stock has fluctuated significantly, reaching a high of $56.22 and a low of $28.53 [4]. Analyst Outlook - Jefferies has lowered the price target for BRKR from $55 to $50, influenced by the recent earnings performance and the decline in EPS, despite the company's ability to exceed revenue estimates [5][6].

Financial Data and Key Metrics Changes - Total revenue increased by 8% in 2025, with product revenue growing by 10% driven by global demand for innovative medicines [7][18] - Core EPS grew by 11%, aligning with full-year guidance [18] - Operating profit increased by 9%, with a focus on operating leverage [20] - Cash flow from operating activities rose by 23% to $14.6 billion [21] - Core gross margin landed at 82%, consistent with expectations [18] Business Line Data and Key Metrics Changes - Oncology revenues reached $25.6 billion, up 14% year-over-year, with Tagrisso, Imfinzi, and Calquence showing significant growth [26][27] - BioPharmaceuticals revenue increased by 5% to $23 billion, with growth medicines outpacing the impact of generic entries [40] - Rare Disease revenue grew by 4% to $9.1 billion, driven by neurology indications and increased patient demand [52] Market Data and Key Metrics Changes - U.S. market saw a 10% growth, while emerging markets outside of China experienced a 22% increase [11] - Europe grew by 7%, and China grew by 4% despite losing Pulmicort to generics [11] - Alliance revenue surged by 38%, reflecting increased contributions from partnered products [18] Company Strategy and Development Direction - The company aims to reach $80 billion in revenue by 2030, with a focus on expanding its pipeline and diversifying its product offerings [7][13] - Significant investments are being made in R&D, particularly in areas like ADCs, cell therapy, and bispecifics [24][50] - The company is prioritizing technologies that will shape the future of medicine, including weight management and cardiovascular treatments [14][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite known headwinds, including patent expirations and market competition [22][23] - The company anticipates continued strong performance in 2026, with core EPS growth projected in the low double digits [22][25] - Management highlighted the importance of a diversified pipeline to mitigate risks associated with product concentration [10] Other Important Information - The company confirmed a second interim dividend of $2.17 per share, with plans to increase the annual declared dividend to $3.30 in 2026 [22] - The company has over 100 ongoing phase III trials, with significant revenue potential from upcoming readouts [12][59] - Management acknowledged the contributions of outgoing head of investor relations, Andy Barnett, and welcomed his successor, Joris [60][61] Q&A Session Summary Question: What are the expectations for growth in the oncology segment? - The oncology segment is expected to continue its strong momentum, with several key approvals and product launches anticipated in 2026 [30][31] Question: How is the company addressing the challenges posed by generic competition? - The company is focusing on expanding its product portfolio and enhancing its R&D efforts to mitigate the impact of generics [40][44] Question: What are the key catalysts for growth in the rare disease segment? - Key catalysts include the anticipated readouts for Ultomiris and Strensiq, as well as ongoing market expansion efforts [52][56]

Core Viewpoint - Revvity reported a total revenue of $2.856 billion for 2025, reflecting a year-on-year growth of 3.7% [2][4]. Financial Performance Overview 2025 Fourth Quarter Performance - The GAAP earnings per share (EPS) for Q4 2025 was $0.87, compared to $0.78 in the same period last year [3]. - Q4 revenue reached $772 million, up from $729 million year-on-year, marking a growth of 5.9% [3][11]. - The GAAP operating profit from continuing operations was $111.7 million, with an operating profit margin of 14.5%, down from 16.3% in the previous year [3][11]. 2025 Full Year Performance - For the full year 2025, the GAAP EPS was $2.07, down from $2.20 in 2024 [4]. - Total revenue for 2025 was $2.856 billion, an increase from $2.755 billion in 2024, representing a growth of 3.7% [4]. - The GAAP operating profit for continuing operations was $357 million, with a profit margin of 12.5% [4]. Business Segment Performance Life Sciences Segment - The Life Sciences segment generated $1.431 billion in revenue for 2025, up from $1.399 billion in 2024, reflecting a growth of 2% [6][8]. - Q4 revenue for the Life Sciences segment was $382 million, compared to $375 million in the same quarter last year, indicating a growth of 2% [7]. Diagnostics Segment - The Diagnostics segment reported $1.425 billion in revenue for 2025, an increase from $1.356 billion in 2024, representing a growth of 5% [8]. - Q4 revenue for the Diagnostics segment was $390 million, up from $355 million year-on-year, showing a significant growth of 10% [9]. 2026 Financial Guidance - The company forecasts total revenue for fiscal year 2026 to be between $2.96 billion and $2.99 billion, with an organic revenue growth rate of 2% to 3% [13]. - Adjusted EPS for 2026 is projected to be between $5.35 and $5.45 [13].

Core Insights - Apple reported record revenue of $143.8 billion for Q1 of fiscal year 2026, a 16% year-over-year increase, with diluted earnings per share (EPS) of $2.84, up 19% [1][4] - CEO Tim Cook highlighted unprecedented demand for iPhones, leading to the best quarter ever for the product across all regions [1][2] Revenue Breakdown - iPhone revenue reached $85.269 billion, a 23% increase year-over-year, marking a historical high [2] - Services revenue was $30.013 billion, up 14% year-over-year, also a record [2] - iPad revenue was approximately $8.595 billion, a 6% increase [2] - Mac revenue was $8.386 billion, down about 7% [2] - Wearables, Home, and Accessories revenue was $11.493 billion, down about 2% [2] - Greater China saw significant growth, with revenue of $25.526 billion, a 38% increase year-over-year [2] Profitability and Cash Flow - Gross margin for the quarter was 48.2%, up from 46.9% year-over-year, with product gross margin at 40.7% and services gross margin at 76.5% [3] - Operating cash flow was approximately $53.9 billion, with nearly $32 billion returned to shareholders through stock buybacks and cash dividends [3] - A cash dividend of $0.26 per share was announced, payable on February 12, 2026 [3] Future Outlook - Apple did not provide formal guidance for the next quarter but emphasized a strong foundation for long-term growth based on user base, service growth, and product satisfaction [4] - The company achieved record results across multiple metrics, making it the largest single fiscal quarter in its history [4]

Financial Data and Key Metrics Changes - Landmark Bancorp reported a net income of $4.7 million for Q4 2025, a significant increase from $3.3 million in Q4 2024, with diluted earnings per share rising to $0.77 [4][9] - For the full year 2025, net income reached $18.8 million or $3.07 per share, marking a 43% increase over 2024 earnings per share [5] - The tangible book value increased to $20.79 per share, up $0.83 from the previous quarter and $4.09 or 24% from year-end 2024 [4][5] - The efficiency ratio improved to 62.7% in 2025 from 69.1% in 2024, indicating better expense management [5] Business Line Data and Key Metrics Changes - Net interest income for Q4 2025 totaled $14.8 million, an increase of $695,000 from Q3 2025, driven by higher asset yields and lower funding costs [9] - Commercial loan production was strong, particularly in commercial real estate, with mortgage originations increasing by 11% year-over-year [6][19] - Non-interest income for Q4 2025 was $3.9 million, a decrease of $169,000 from the prior quarter, primarily due to a loss on the sale of investment securities [12] Market Data and Key Metrics Changes - Deposits totaled $1.4 billion at December 31, 2025, increasing by $63.4 million in Q4, with interest checking and money market deposits rising significantly [15][16] - Non-interest-bearing deposits accounted for 26.3% of total deposits at year-end [16] - The Kansas economy remains healthy, with an unemployment rate of 3.8% as of November 30, 2025 [21] Company Strategy and Development Direction - The company plans to continue investing in its associates and make strategic investments to enhance customer service and capitalize on growth opportunities in its markets [23] - Management emphasized the importance of maintaining a strong and resilient balance sheet while proactively monitoring credit quality to minimize future losses [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in building on the foundation set in 2025 and highlighted the dedication of associates in serving customers and strengthening communities [23] - The company remains focused on addressing non-performing loans and improving the overall quality of its loan portfolio [20] Other Important Information - The board of directors declared a cash dividend of $0.21 per share, marking the 98th consecutive quarterly cash dividend since the company's formation [8] - The allowance for credit losses stood at $12.5 million, representing 1.12% of gross loans, indicating a strong position in managing credit risk [20] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating that the call may have concluded without a formal Q&A segment [24]

Core Viewpoint - Danaher Corporation is experiencing strong financial performance, leading to a positive outlook from Evercore ISI, which has maintained an "Outperform" rating and raised its price target to $254 [1][6]. Financial Performance - Danaher reported fourth-quarter adjusted earnings per share (EPS) of $2.23, slightly exceeding the Zacks Consensus Estimate of $2.22 [2]. - Net sales for the quarter reached $6.84 billion, surpassing expectations of $6.79 billion, marking a 4.5% increase from the previous year [2]. - For the full year 2025, Danaher achieved net revenues of $24.6 billion, reflecting a 3% year-over-year increase [3]. Segment Performance - The Biotechnology segment saw a revenue surge of 9%, while the Diagnostics segment experienced a profit increase of 14.3% [3]. - The company projects low single-digit core sales growth in the first quarter of 2026, with adjusted EPS expected to range from $8.35 to $8.50 [3][6]. Stock Performance - Danaher's stock is currently priced at $223.995, reflecting a decrease of approximately 4.99% with a change of -$11.75 [4]. - The stock has fluctuated between a low of $223.09 and a high of $235.07 today, with a market capitalization of approximately $160.39 billion [4]. Market Dynamics - Foreign-currency translations positively impacted the quarter's results by 2.5%, while acquisitions and divestitures had a slight negative effect of 0.5% [5]. - The trading volume for the day is 5,105,026 shares on the NYSE, indicating active investor interest [5].